In patients with type 2 diabetes, chronic kidney disease and albuminuria, is finerenone, a selective minerocorticoid receptor antagonist, effective and safe for lowering CKD progression?

被引：0
|
作者：
Lanthier, L. [1 ]
Plourde, M-E [2 ]
Cauchon, M. [3 ]
机构：
[1] Univ Sherbrooke, Dept Med Specialise, Serv Med Interne Gen, Sherbrooke, PQ, Canada
[2] Univ Sherbrooke, Dept Med Nucl & Radiobiol, Serv Radiooncol, Sherbrooke, PQ, Canada
[3] Univ Laval, Dept Med Familiale & Med Urgence, Quebec City, PQ, Canada
来源：
REVUE DE MEDECINE INTERNE | 2021年 / 42卷 / 02期
关键词：
NEPHROPATHY;
D O I：
10.1016/j.revmed.2020.12.013
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：144 / 145
页数：2
相关论文
共 50 条
  • [1] Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
    DeFronzo, Ralph A.
    Bakris, George L.
    DIABETES OBESITY & METABOLISM, 2022, 24 (07): : 1197 - 1205
  • [2] Finerenone: a mineralocorticoid receptor antagonist for the treatment of chronic kidney disease associated with type 2 diabetes
    Lerma, Edgar V.
    Wilson, Daniel J.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2022, 15 (05) : 501 - 513
  • [3] Albuminuria and chronic kidney disease progression in patients with type 2 diabetes mellitus
    Kawada, Tomoyuki
    CLINICAL AND EXPERIMENTAL NEPHROLOGY, 2024, 28 (10) : 1062 - 1063
  • [4] Finerenone: Efficacy of a New Nonsteroidal Mineralocorticoid Receptor Antagonist in Treatment of Patients With Chronic Kidney Disease and Type 2 Diabetes
    Dey, Subo
    Garg, Jasmine
    Wang, Andy
    Holzner, Eva
    Frishman, William H.
    Aronow, Wilbert S.
    CARDIOLOGY IN REVIEW, 2024, 32 (03) : 285 - 288
  • [5] Albuminuria Is Associated with Rapid Chronic Kidney Disease Progression in Patients with Type 2 Diabetes
    Sohn, Tae Seo
    Oh, Su Jin
    Seok, Hannah
    Park, Ha Neul
    Lee, Jeong Eun
    Ko, Yoo Mi
    Son, Hyun Shik
    DIABETES, 2014, 63 : A575 - A575
  • [6] Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)
    Andress, Dennis L.
    Coll, Blai
    Pritchett, Yili
    Brennan, John
    Molitch, Mark
    Kohan, Donald E.
    LIFE SCIENCES, 2012, 91 (13-14) : 739 - 742
  • [7] Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus
    Wanner, C.
    Nitschmann, S.
    INTERNIST, 2021, 62 (05): : 577 - 580
  • [8] NATURAL HISTORY OF CHRONIC KIDNEY DISEASE WITH TYPE 2 DIABETES PROGRESSION WITH ALBUMINURIA
    Marx, Steven
    Manthena, Shivaji
    Newmark, Jay
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 137 - 137
  • [9] FIDELIO STUDY: SIGNIFICANCE AND PLACE OF FINERENONE AS NONSTEROIDAL MINERALOCORTICOID RECEPTOR ANTAGONIST IN THERAPY OF PATIENTS WITH CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES
    Shamkhalova, Minara S.
    Sukhareva, Olga Yu.
    Yevloyeva, Madina I.
    DIABETES MELLITUS, 2023, 26 (06): : 603 - 614
  • [10] The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease
    Barrera-Chimal, Jonatan
    Gerarduzzi, Casimiro
    Rossignol, Patrick
    Jaisser, Frederic
    CLINICAL SCIENCE, 2022, 136 (12) : 1005 - 1017
12345